Skip to content

The effect and possible mechanism of CX3CL1 chemokine on cognitive function in patients with chronic pain

The effect and possible mechanism of CX3CL1 chemokine on cognitive function in patients with chronic pain

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500096688
Enrollment
Unknown
Registered
2025-02-05
Start date
2025-02-08
Completion date
Unknown
Last updated
2025-02-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cognitive impairment

Interventions

Chronic pain group:Group by: Patients with knee or hip surgery with a VAS score of >=4 (grade III or IV) and a duration of >=6 weeks
control group:Group by: Patients with knee or hip surgery with a VAS score of <3

Sponsors

Anhui Public Health Clinical Center
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Age between 18-60 years old; 2. Able to understand the research objectives and sign informed consent forms; 3. Knee or hip joint surgery needs to be performed under combined spinal and epidural anesthesia; 4. Able to communicate well with researchers and comply with the entire experimental requirements.

Exclusion criteria

Exclusion criteria: 1. There are contraindications related to epidural anesthesia; 2. Previous comorbidities of internal medicine such as coronary heart disease and severe cerebrovascular disease; 3. Combine pain in areas other than joint pain, such as headaches, lower back pain, etc; 4. There are contraindications for magnetic resonance imaging (such as non magnetic compatible metal implants, claustrophobia, etc.); 5. History of alcohol abuse (alcohol consumption >= 1000 g /day); 6. History of previous head trauma; 7. Education level below primary school; 8. Female patients are in the perinatal period; 9. Communication barriers or inability to cooperate; 10. Recently participated in other clinical trials.

Design outcomes

Primary

MeasureTime frame
MoCA rating;Anxiety self-rating scale score;Self-Rating Depression Scale;Head magnetic resonance imaging;CX3CL1;IL-6;

Countries

China

Contacts

Public ContactWeiwei Wu

Anhui Public Health Clinical Center

wuweiwei_wy@163.com+86 188 5691 0051

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026